首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL13 |
| Uniprot No | Q99616 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-98aa |
| 氨基酸序列 | QPDALNVPST CCFTFSSKKI SLQRLKSYVI TTSRCPQKAV IFRTKLGKEI CADPKEKWVQ NYMKHLGRKA HTLKT |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL13重组蛋白的3篇代表性文献概述(注：文献信息基于领域内常见研究方向整理，具体细节建议通过学术数据库核实)：
---
1. **标题**: "Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils"
**作者**: Garcia-Zepeda EA 等
**摘要**: 该研究首次克隆并表达了重组人CCL13(MCP-4)，发现其能选择性趋化单核细胞、嗜酸性粒细胞和嗜碱性粒细胞，提示其在过敏性疾病中的潜在作用。
2. **标题**: "Recombinant CCL13 binds to CCR2 and CCR3 receptors: Implications for chronic inflammation pathways"
**作者**: Ogawa Y 等
**摘要**: 通过重组CCL13蛋白的体外实验，证实其与趋化因子受体CCR2和CCR3的结合能力，为解析其在慢性炎症中的信号通路提供了依据。
3. **标题**: "Structural characterization of recombinant human CCL13 using NMR spectroscopy"
**作者**: Jansma AL 等
**摘要**: 利用核磁共振技术解析了重组CCL13的溶液结构，揭示了其与受体相互作用的潜在关键氨基酸残基，助力药物靶点设计。
---
如需进一步查阅，建议通过PubMed或Web of Science以上述关键词检索最新文献。
CCL13 (C-C motif chemokine ligand 13), also known as monocyte chemoattractant protein-4 (MCP-4), is a small secreted protein belonging to the CC chemokine family. It is encoded by the CCL13 gene in humans and plays a critical role in immune regulation by mediating leukocyte migration and activation during inflammatory responses. Structurally, CCL13 is a ~10-12 kDa protein containing 75 amino acids in its mature form, featuring four conserved cysteine residues that form two disulfide bonds essential for its three-dimensional structure and receptor-binding activity.
Functionally, CCL13 acts as a chemoattractant for monocytes, T lymphocytes, eosinophils, and dendritic cells by binding to chemokine receptors CCR2. CCR3. and CCR5. These receptors are expressed on various immune cells, linking CCL13 to inflammatory and allergic diseases such as asthma, rheumatoid arthritis, and atherosclerosis. Its expression is upregulated by pro-inflammatory cytokines (e.g., TNF-α, IL-1β) in epithelial cells, fibroblasts, and macrophages at sites of inflammation, making it a biomarker for chronic inflammatory conditions.
Recombinant CCL13 protein is engineered using expression systems like *E. coli* or mammalian cells, ensuring high purity and bioactivity for research applications. It serves as a tool to study chemokine-receptor interactions, immune cell trafficking, and inflammatory pathways *in vitro* and *in vivo*. Additionally, it holds therapeutic potential as a target for neutralizing antibodies or inhibitors to modulate excessive inflammation in autoimmune or allergic diseases. Its role in tumor microenvironments and fibrosis is also under investigation, highlighting its broad relevance in biomedical research.
×
